Full list of publications

• 1. Kunst NR, Lindvik H, Carlsen KH, Haaland G, Jørgensen E, Carlsen KCL. Cost-effectiveness of diagnostic algorithms for peanut allergy in children. Journal of Allergy and Clinical Immunology. 2019. doi:10.1016/j.jaci.2018.10.050
• 2. Kunst NR, Alarid-Escudero F, Paltiel AD, Wang SY. A value of information analysis of research on the 21-gene assay for breast cancer management. Value in Health. 2019. Editors’ Choice. doi:10.1016/j.jval.2019.05.004

• 3. Heath A, Kunst N, Jackson C, Strong M, Alarid-Escudero F, Goldhaber-Fiebert JD, Baio G, Menzies NA, Jalal J. Calculating the Expected Value of Sample Information in Practice: Considerations from Three Case Studies. Medical Decision Making. 2020. doi:10.1177/0272989X20912402
• 4. Kunst N, Wilson E, Glynn D, Alarid-Escudero F, Baio G, Brennan A, Fairley M, Goldhaber-Fiebert JD, Jackson C, Jalal H, Menzies NA, Strong M, Thom H, Heath A. Computing the expected value of sample information efficiently: Practical guidance and recommendations for four model-based methods. Value in Health. 2020. Editors’ Choice. doi:10.1016/j.jval.2020.02.010
• 5. Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Richman IB, Gross CP. Use and costs of breast cancer screening for women in their 40s in a privately insured US population. JAMA Internal Medicine. 2020. doi:10.1001/jamainternmed.2020.0262
• 6. Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf D, Neumann PJ. Perspective and costing in cost-effectiveness analysis, 1974-2018. PharmacoEconomics. 2020. doi:10.1007/s40273-020-00942-2
• 7. Kunst N, Alarid-Escudero F, Aas E, Coupe VMH, Schrag D, Kuntz KM. Estimating population-based recurrence rates of colorectal cancer over time in the US. Cancer Epidemiology, Biomarkers & Prevention. 2020. doi:10.1158/1055-9965.EPI-20-0490
• 8. Kunst N, Gross CP. Breast Cancer Screening and Health Care Costs—Reply. JAMA Internal Medicine. 2020. doi:10.1001/jamainternmed.2020.2355
• 9. Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-effectiveness of different neoadjuvant followed by adjuvant treatment strategies for women with HER2-positive breast cancer. JAMA Network Open. 2020. doi:10.1001/jamanetworkopen.2020.27074
• 10. Richman IB, Long JB, Hoag JR, Upneja A, Hooley R, Xu X, Kunst N, Aminawung JA, Kyanko KA, Busch SH, Gross CP. Comparative effectiveness of digital breast tomosynthesis for breast cancer screening among women 40-64 years old. JNCI: Journal of the National Cancer Institute. 2021. doi:10.1093/jnci/djab063
• 11. Heath A, Strong M, Glynn D, Kunst N, Welton N, Goldhaber-Fiebert JD. Simulating Study Data to Support Expected Value of Sample Information Calculations: A Tutorial. Medical Decision Making. 2021. doi:10.1177/0272989X211026292
• 12. Kunst N, Long JB, Xu X, Busch SH, Kyanko KA, Lindau ST, Richman IB, Gross CP. Understanding variation in the cost of breast cancer screening among privately insured women in the US. Medical Care. 2021. doi:10.1097/MLR.0000000000001506
• 13. Tuffaha H, Rothery C, Kunst N, Jackson C, Strong M, Birch S. A review of web-based tools for value of information analysis. Applied Health Economics and Health Policy. 2021. doi:10.1007/s40258-021-00662-4
• 14. Upneja A, Long JB, Aminawung JA, Kyanko KA, Kunst N, Xu X., Busch SH, Gross CP, Richman IB. Comparative effectiveness of digital breast tomosynthesis and mammography among older women. Journal of General Internal Medicine. 2021. doi:10.1007/s11606-021-07132-6
• 15. Jongeneel G, Greuter MJE, Kunst N, van Erning FN, Koopman M, Medema JP, Vermeulen L, Vink GR, Punt CJA, Coupé VMH. Early cost-effectiveness analysis of risk-based selection for adjuvant treatment in stage II colon cancer: the potential of consensus molecular subtypes. Cancer Epidemiology, Biomarkers & Prevention. 2021. doi:10.1158/1055-9965.EPI-21-0078
• 16. Richman IB, Long JB, Kunst N, Kyanko K, Xu X, Busch S, Gross CP. Trends in breast cancer costs among privately insured women, 40-64. JAMA Internal Medicine. 2021. doi:10.1001/jamainternmed.2021.4832
• 17. Yang SC, Kunst N, Gross CP, Wang JD, Su WC, Wang SY. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy for non-small cell lung cancer. 2022. doi: 10.3389/fonc.2021.760686
• 18. Wolff HB, Qendri V, Kunst N, Alarid-Escudero F, Coupé VMH. Methods for communicating the impact of parameter uncertainty in a multiple strategies cost-effectiveness comparison. 2022. doi: 10.1177/0272989X221100112
• 19. Dijk SW, Krijkamp EM, Kunst N, Gross P, Wong JB, Hunink MGM. Emerging Therapies for COVID-19: the value of more clinical research compared to immediate implementation. 2022. doi: 10.1016/j.jval.2022.03.016
• 20. Kunst N, Stout NK, O’Brien G, Christensen KD, McMahon PM, Wu AC, Diller L, Yeh JM. Population-based TP53 variant screening: Cost-effectiveness and clinical benefit of newborn screening for Li-Fraumeni syndrome. 2022. doi: 10.1093/jnci/djac013
• 21. Knauss T, Hansen BT, Pedersen K, Aasbø G, Kunst N, Burger EA. The cost-effectiveness of opt-in and send-to-all HPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: The Equalscreen randomized controlled trial. Gynecologic Oncology. (In press)
• 22. Chehayeb RJ, Hood A, Wang X, Miksad R, Mougalian SS, Lustberg MB, Wang SY, Greenup RA, Pusztai L, Kunst N. Treatment sequencing patterns and associated direct medical costs of metastatic breast cancer care in the United States, 2011 to 2021. JAMA Network Open. (In press)